supplementary figure 1

Supplementary Figure 1

0

10

20

30

40

50

60

70

24h 48h 72h

%ap

op

tosi

s

0nM1nM2.5nM5nM7.5nM10nM

Docetaxel

0

10

20

30

40

50

60

70

80

24h 48h 72h 96h

% a

po

pto

sis

0 µM2.5 µM5 µM10 µM25 µM50 µM

LovastatinA

B

HepG2

0

2

4

6

8

10

12

14

control L 12.5µM D 5nM L 12.5µM+ D 5nM

Cas

pas

e 3/

7 ac

tivi

ty

(arb

itra

ry u

nit

s)

H322

0123456789

control L 12.5µM D 5nM L 12.5µM + D 5nM

Cas

pas

e 3/

7 ac

tivi

ty

(arb

itra

ry u

nit

s)

24 h48 h

HeLa

0123456789

control L 12.5µM D 5nM L 12.5µM+ D 5nM

Cas

pas

e 3/

7 ac

tivi

ty

(arb

itra

ry u

nit

s)

Supplementary Figure 2

0

10

20

30

40

50

60

70

80

% a

po

pto

sis

control L 12.5µM V 0.5nML 12.5µM+ V 0.5nM

V 1nML 12.5µM+ V 1nM

***

***

***

***

***

† †

# # #

# #

† †

Supplementary Figure 3

Supplementary Figure 4

******# # #

***

control verapamil vinblastine vinblastine +verapamil

0

5

10

15

20

25

30

35

40

45

% a

popt

osis

HGT-1HGT-1-D5

Supplementary Figure 5

HGT-1 HGT-1-D5

Signal patterns

2O2G 3O3G 4O4G 3O1G

HGT-1 100

HGT-1-D5 42 47.5 8 2.5